Solventum (SOLV) to Release Quarterly Earnings on Thursday

Solventum (NYSE:SOLV) is anticipated to release its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Solventum to post earnings of $1.50 per share and revenue of $1.9613 billion for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Solventum Trading Up 1.1%

Shares of Solventum stock opened at $73.42 on Wednesday. The firm’s 50 day simple moving average is $78.90 and its two-hundred day simple moving average is $76.19. The firm has a market capitalization of $12.73 billion, a price-to-earnings ratio of 8.46, a PEG ratio of 6.67 and a beta of 0.35. Solventum has a 12-month low of $60.70 and a 12-month high of $88.20. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 1.03.

Solventum announced that its Board of Directors has approved a stock repurchase plan on Thursday, November 20th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the company to purchase up to 7.5% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Institutional Trading of Solventum

Several institutional investors have recently modified their holdings of the stock. DRW Securities LLC purchased a new position in Solventum in the 4th quarter valued at $298,000. Mill Capital Management LLC acquired a new stake in shares of Solventum in the fourth quarter valued at about $201,000. Wimmer Associates 1 LLC purchased a new position in shares of Solventum in the fourth quarter worth about $203,000. Equitable Holdings Inc. acquired a new position in Solventum during the third quarter worth about $208,000. Finally, Vident Advisory LLC purchased a new stake in Solventum during the 4th quarter valued at about $210,000.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. Wall Street Zen cut Solventum from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Mizuho set a $100.00 target price on Solventum and gave the stock an “outperform” rating in a research note on Tuesday, January 20th. BTIG Research upgraded Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a research report on Tuesday, December 2nd. Finally, Piper Sandler restated an “overweight” rating on shares of Solventum in a research report on Wednesday, December 17th. Seven research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Solventum has an average rating of “Hold” and an average target price of $90.83.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.